Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present) One of the most common and deadliest disease on record is lung cancer. According to estimates with increasing incidence each year, about 85% of lung cancer cases are non-small cell lung cancer type, and about […]
Type 2 Diabetes Mellitus
Overview of Type 2 Diabetes Mellitus Type 2 diabetes mellitus is the most common type of diabetes, in which the blood glucose, is too high. This chronic condition may lead to disorders of the circulatory, nervous and immune systems, and affects your everyday life. In type 2 diabetes there are mainly 2 associated problems; body […]
Parsian Pharama Review of CDK4/6 Inhibitors Citing to the Recent Articles
Parsian pharama review of CDK4-6 inhibitors citing to the recent articles One of the most common cancers among women is Breast cancer. Sometimes the average risk of developing breast cancer in a woman in the United States in her lifespan is about 13%. More than 70% of breast cancer cases are Hormone receptor–positive (HR+) types, […]
US FDA Approved Empagliflozin
The U.S. FDA Approved Empagliflozin for Wider Range of Patients with Heart Failure Abstracts: On February 24, 2022, The U.S. FDA approved an expanded indication for empagliflozin which is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to reduce the risk of Cardiovascular (CV) death and Heart failure (HF) hospitalization in adults with HF with reduced or […]
Breaking news; U.S FDA advisory panel narrowly endorses Molnupiravir
Breaking news; U.S FDA advisory panel narrowly endorses Molnupiravir U.S FDA advisory panel narrowly endorses Molnupiravir, for Mild to Moderate COVID-19 in High Risk patients, despite reduced efficacy and safety questions . A Food and Drug Administration advisory panel on Tuesday narrowly endorsed the use of Merck and Ridgeback’s at-home Covid treatment pill, despite questions about […]
Aromatase Inhibitors
Parsian pharma review of aromatase inhibitors (AIs) citing to the recent articles regard this subject: Key points that led Parsian pharma to choose Letrozole over other aromatase inhibitors Cell growth in breast cancer is essentially derived by estrogen in both premenopausal and postmenopausal women. Most of the breast cancer cases are among postmenopausal women, […]